|
تقييم Argenx SE (Argx) DCF
NL | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
argenx SE (ARGX) Bundle
قم بتبسيط تقييم argenx SE (ARGX) باستخدام حاسبة DCF القابلة للتخصيص! تتميز بالبيانات المالية الحقيقية لـ argenx SE (ARGX) ومدخلات التنبؤ القابلة للتعديل، يمكنك اختبار السيناريوهات والكشف عن القيمة العادلة لـ argenx SE (ARGX) في دقائق.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81.1 | 46.5 | 516.1 | 426.3 | 1,272.7 | 1,718.2 | 2,319.6 | 3,131.5 | 4,227.6 | 5,707.3 |
| Revenue Growth, % | 0 | -42.59 | 1008.8 | -17.4 | 198.56 | 35 | 35 | 35 | 35 | 35 |
| EBITDA | -184.4 | -624.4 | -326.3 | -604.0 | -224.2 | -1,308.7 | -1,766.8 | -2,385.2 | -3,220.1 | -4,347.2 |
| EBITDA, % | -227.48 | -1341.56 | -63.23 | -141.7 | -17.62 | -76.17 | -76.17 | -76.17 | -76.17 | -76.17 |
| Depreciation | 2.5 | 4.4 | 6.1 | 108.3 | 115.7 | 165.6 | 223.6 | 301.8 | 407.5 | 550.1 |
| Depreciation, % | 3.1 | 9.41 | 1.18 | 25.4 | 9.09 | 9.64 | 9.64 | 9.64 | 9.64 | 9.64 |
| EBIT | -186.9 | -628.8 | -332.4 | -712.3 | -339.9 | -1,344.0 | -1,814.4 | -2,449.5 | -3,306.9 | -4,464.4 |
| EBIT, % | -230.58 | -1350.98 | -64.41 | -167.1 | -26.71 | -78.22 | -78.22 | -78.22 | -78.22 | -78.22 |
| Total Cash | 1,557.4 | 2,071.9 | 2,425.1 | 2,275.4 | 3,300.1 | 1,718.2 | 2,319.6 | 3,131.5 | 4,227.6 | 5,707.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 33.1 | 7.7 | 33.9 | 287.8 | 518.1 | 591.7 | 798.8 | 1,078.4 | 1,455.9 | 1,965.6 |
| Account Receivables, % | 40.81 | 16.59 | 6.58 | 67.51 | 40.71 | 34.44 | 34.44 | 34.44 | 34.44 | 34.44 |
| Inventories | .0 | 26.1 | 113.2 | 237.0 | 322.3 | 546.5 | 737.8 | 996.0 | 1,344.6 | 1,815.3 |
| Inventories, % | 0 | 56.18 | 21.93 | 55.59 | 25.32 | 31.81 | 31.81 | 31.81 | 31.81 | 31.81 |
| Accounts Payable | 68.1 | 214.1 | 216.7 | 195.9 | 254.8 | 1,003.4 | 1,354.6 | 1,828.8 | 2,468.9 | 3,333.0 |
| Accounts Payable, % | 84.03 | 460.05 | 42 | 45.95 | 20.02 | 58.4 | 58.4 | 58.4 | 58.4 | 58.4 |
| Capital Expenditure | -48.5 | -5.7 | -126.0 | -107.7 | -45.5 | -430.6 | -581.4 | -784.8 | -1,059.6 | -1,430.4 |
| Capital Expenditure, % | -59.82 | -12.22 | -24.42 | -25.28 | -3.57 | -25.06 | -25.06 | -25.06 | -25.06 | -25.06 |
| Tax Rate, % | 3.1 | 3.1 | 3.1 | 3.1 | 3.1 | 3.1 | 3.1 | 3.1 | 3.1 | 3.1 |
| EBITAT | -192.5 | -632.1 | -339.5 | -693.0 | -329.3 | -1,328.4 | -1,793.4 | -2,421.1 | -3,268.5 | -4,412.6 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -203.5 | -488.2 | -570.1 | -1,091.0 | -515.8 | -1,142.6 | -2,198.3 | -2,967.8 | -4,006.6 | -5,409.1 |
| WACC, % | 5.17 | 5.17 | 5.17 | 5.17 | 5.17 | 5.17 | 5.17 | 5.17 | 5.17 | 5.17 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -13,105.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -5,517 | |||||||||
| Terminal Value | -174,204 | |||||||||
| Present Terminal Value | -135,413 | |||||||||
| Enterprise Value | -148,518 | |||||||||
| Net Debt | -2,106 | |||||||||
| Equity Value | -146,413 | |||||||||
| Diluted Shares Outstanding, MM | 57 | |||||||||
| Equity Value Per Share | -2,561.04 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Argenx SE’s financial data pre-filled to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you.
- Customizable and Professional: A refined Excel model that caters to your valuation requirements.
- Built for Analysts and Investors: Perfect for testing projections, validating strategies, and enhancing efficiency.
Key Features
- 🔍 Real-Life ARGX Financials: Pre-filled historical and projected data for argenx SE (ARGX).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate argenx’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize argenx’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- 1. Access the Template: Download and open the Excel file containing argenx SE's (ARGX) financial data.
- 2. Modify Assumptions: Adjust critical inputs such as growth rates, WACC, and capital expenditures.
- 3. View Results Instantly: The DCF model automatically computes intrinsic value and NPV based on your inputs.
- 4. Explore Scenarios: Evaluate various forecasts to assess different valuation results.
- 5. Present with Assurance: Share professional valuation insights to enhance your decision-making process.
Why Choose This Calculator for argenx SE (ARGX)?
- Comprehensive Tool: Offers DCF, WACC, and financial ratio analyses all in one easy-to-use platform.
- Customizable Inputs: Modify yellow-highlighted cells to explore different financial scenarios.
- Detailed Insights: Automatically computes argenx SE’s intrinsic value and Net Present Value.
- Preloaded Data: Historical and projected data provide reliable starting points for analysis.
- Professional Quality: Perfect for financial analysts, investors, and business consultants focused on argenx SE (ARGX).
Who Should Use This Product?
- Investors: Evaluate argenx SE’s (ARGX) valuation prior to making investment decisions.
- CFOs and Financial Analysts: Optimize valuation workflows and assess financial forecasts.
- Startup Founders: Understand the valuation methods applied to biotech firms like argenx SE.
- Consultants: Provide clients with comprehensive valuation analyses for informed decision-making.
- Students and Educators: Utilize current data to practice and instruct on valuation methodologies.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled argenx SE (ARGX) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for argenx SE (ARGX).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.